Gut microbiome alpha-diversity is not a marker of Parkinson's disease and multiple sclerosis

Show full item record



Plassais , J , Gbikpi-Benissan , G , Figarol , M , Scheperjans , F , Gorochov , G , Derkinderen , P & Cervino , A C L 2021 , ' Gut microbiome alpha-diversity is not a marker of Parkinson's disease and multiple sclerosis ' , Brain communications , vol. 3 , no. 2 , 113 .

Title: Gut microbiome alpha-diversity is not a marker of Parkinson's disease and multiple sclerosis
Author: Plassais, Jonathan; Gbikpi-Benissan, Guillaume; Figarol, Marine; Scheperjans, Filip; Gorochov, Guy; Derkinderen, Pascal; Cervino, Alessandra C. L.
Contributor organization: Clinicum
HUS Neurocenter
Department of Neurosciences
Neurologian yksikkö
Date: 2021
Language: eng
Number of pages: 14
Belongs to series: Brain communications
ISSN: 2632-1297
Abstract: The gut-brain axis may play a central role in the pathogenesis of neurological disorders. Dozens of case-control studies have been carried out to identify bacterial markers by the use of targeted metagenomics. Alterations of several taxonomic profiles have been confirmed across several populations, however, no consensus has been made regarding alpha-diversity. A recent publication has described and validated a novel method based on richness and evenness measures of the gut microbiome in order to reduce the complexity and multiplicity of alpha-diversity indices. We used these recently described richness and evenness composite measures to investigate the potential link between gut microbiome alpha-diversity and neurological disorders and to determine to what extent it could be used as a marker to diagnose neurological disorders from stool samples. We performed an exhaustive review of the literature to identify original published clinical studies including 16S rRNA gene sequencing on Parkinson's disease, multiple Sclerosis and Alzheimer's disease. Richness and evenness factors loadings were quantified from sequencing files in addition with the Shannon diversity index. For each disease, we performed a meta-analysis comparing the indices between patients and healthy controls. Seven studies were meta-analysed for Parkinson's disease, corresponding to 1067 subjects (631 Parkinson's Disease/436 healthy controls). Five studies were meta-analysed for multiple sclerosis, corresponding to 303 subjects (164 Multiple Sclerosis/139 healthy controls). For Alzheimer's disease, the meta-analysis was not done as only two studies matched our criteria. Neither richness nor evenness was significantly altered in Parkinson's disease and multiple sclerosis patients in comparison to healthy controls (P-value > 0.05). Shannon index was neither associated with neurological disorders (P-value > 0.05). After adjusting for age and sex, none of the alpha-diversity measures were associated with Parkinson's Disease. This is the first report investigating systematically alpha-diversity and its potential link to neurological disorders. Our study has demonstrated that unlike in other gastro-intestinal, immune and metabolic disorders, loss of bacterial diversity is not associated with Parkinson's disease and multiple sclerosis.
Subject: Parkinson's disease
multiple sclerosis
16S rRNA gene amplicon sequencing
3112 Neurosciences
3124 Neurology and psychiatry
Peer reviewed: Yes
Usage restriction: openAccess
Self-archived version: publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
fcab113.pdf 1011.Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record